Insider Selling: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Sells $68,670.75 in Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75. Following the sale, the insider now directly owns 3,084,107 shares in the company, valued at approximately $46,292,446.07. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Monday, April 22nd, De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00.

enGene Stock Down 3.3 %

Shares of ENGN opened at $14.75 on Thursday. enGene Holdings Inc. has a 12-month low of $6.69 and a 12-month high of $43.00. The firm has a 50-day moving average price of $16.23.

Institutional Investors Weigh In On enGene

A number of hedge funds have recently modified their holdings of the company. Fcpm Iii Services B.V. purchased a new position in enGene during the fourth quarter worth about $80,097,000. BVF Inc. IL purchased a new position in enGene during the fourth quarter worth about $20,777,000. Omega Fund Management LLC purchased a new position in enGene during the fourth quarter worth about $10,441,000. Finally, Vivo Capital LLC purchased a new position in shares of enGene in the fourth quarter valued at approximately $6,264,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on ENGN shares. Morgan Stanley began coverage on shares of enGene in a report on Friday, March 8th. They issued an “overweight” rating and a $40.00 price objective on the stock. UBS Group initiated coverage on shares of enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 price objective for the company. Wells Fargo & Company initiated coverage on shares of enGene in a research report on Monday. They issued an “overweight” rating and a $30.00 target price for the company. Guggenheim initiated coverage on shares of enGene in a research report on Monday, April 15th. They issued a “buy” rating and a $34.00 target price for the company. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $34.40.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.